| Literature DB >> 35359744 |
Nury N Olaya-Galán1,2, Skyler Blume3, Kan Tong3, HuaMin Shen3, Maria F Gutierrez2, Gertrude C Buehring3.
Abstract
Evidence of the presence of bovine leukemia virus (BLV) in human beings and its association with breast cancer has been published in the literature, proposing it as a zoonotic infection. However, not enough evidence exists about transmission pathways nor biological mechanisms in human beings. This study was aimed at gathering experimental evidence about susceptibility of human cell lines to BLV infection. Malignant and non-malignant human cell lines were co-cultured with BLV-infected FLK cells using a cell-to-cell model of infection. Infected human cell lines were harvested and cultured for 3 to 6 months to determine stability of infection. BLV detection was performed through liquid-phase PCR and visualized through in situ PCR. Seven out of nine cell lines were susceptible to BLV infection as determined by at least one positive liquid-phase PCR result in the 3-month culture period. iSLK and MCF7 cell lines were able to produce a stable infection throughout the 3-month period, with both cytoplasmic and/or nuclear BLV-DNA visualized by IS-PCR. Our results support experimental evidence of BLV infection in humans by demonstrating the susceptibility of human cells to BLV infection, supporting the hypothesis of a natural transmission from cattle to humans.Entities:
Keywords: bovine leukemia virus; cell-to-cell infection; human cell lines; in vitro infection; zoonotic potential
Year: 2022 PMID: 35359744 PMCID: PMC8964291 DOI: 10.3389/fmicb.2022.793348
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Cell lines used in in vitro infection experiments and growth conditions.
| Cell line | Cell/tissue type | Biological status | Medium + | Passage |
| RaJi | B cell—Lymphoblast | Burkitt’s lymphoma + EBV | RPMI-1640 | 2–3 |
| HS-27 | Fibroblast—skin | Non-malignant | DMEM | 7–8 |
| MCF 102A | Epithelial—mammary gland | Non-malignant | DMEM/F12, 1:1 | 3–4 |
| MCF 7 (ATCC HTB-22) | Epithelial—mammary gland | Adenocarcinoma | DMEM | 4–5 |
| CaSki | Epithelial—cervix | Epidermoid carcinoma + HPV | RPMI-1640 | 3–4 |
| G361 | Epithelial—skin | Malignant melanoma | MEM | 3–4 |
| 293T | Epithelial—embryonic kidney | Non-malignant + adenovirus | DMEM | 2–3 |
| DLD-I | Epithelial—colon | Colorectal carcinoma | RPMI-1640 | 4–5 |
| iSLK | Epithelial—kidney | Renal carcinoma + | DMEM | 4–5 |
Evidence of BLV-GRE genomic region in human cell lines after infection through nPCR in a follow-up of 12 weeks post-infection.
| Cell line | Replicate | Evidence of BLV post-infection | ||||
| t0 | Week 2 | Week 4 | Week 8 | Week 12 | ||
| RaJi (ATCC CCL-86) | 1 | Pos | Pos | Neg | Neg | Neg |
| 2 | Pos | Pos | Neg | Neg | Neg | |
| HS-27 (ATCC CRL-1634) | 1 | Pos | Pos | Pos | Pos | Neg |
| 2 | Pos | Pos | Pos | Neg | Neg | |
| MCF 102A (ATCC CRL-10781) | 1 | Pos | Pos | Pos | Neg | Neg |
| 2 | Pos | Pos | Pos | Neg | Neg | |
| MCF 7 (ATCC HTB-22) | 1 | Pos | Pos | Pos | Pos | Pos |
| 2 | Pos | Pos | Pos | Neg | Neg | |
| CaSki (ATCC CRL-1550) | 1 | Neg | – | – | – | – |
| 2 | Neg | – | – | – | – | |
| G361 (ATCC CRL-1424) | 1 | Neg | – | – | – | – |
| 2 | Neg | – | – | – | – | |
| 293T (ATCC CRL-3216) | 1 | Pos | Neg | Neg | Neg | Neg |
| 2 | Pos | Pos | Neg | Neg | Neg | |
| DLD-I (ATCC CCL-221) | 1 | Pos | Pos | Pos | Neg | Neg |
| 2 | Pos | Pos | Pos | Neg | Neg | |
| iSLK | 1 | Pos | Pos | Pos | Pos | Pos |
| 2 | Pos | Pos | Pos | Pos | Pos | |
FIGURE 1Bovine leukemia virus genes’ fragments for infected human cell lines at time 0 post-infection. 1.5% agarose electrophoresis gels with representative results per cell line. Results are shown at 48 hpi of the TransWell system. Each infection of the cell lines was repeated twice in two independent moments. DNA from FLK cell line was used as a positive control for PCR reactions.
FIGURE 2Three-month follow-up of BLV infection in human cell lines with GRE region. Gel electrophoresis of PCR product (285 bp) run on 1.5% agarose TBE gel, stained with ethidium bromide. Lanes in order are of DNA extracted 2 weeks, 1 month, 2 months, and 3 months after TransWell infection. Notice the high intensity of the bands on iSLK and MCF-7 cell lines. In 293T cell line, viral infection was lost after week 4 post-infection.
FIGURE 3Evidence of BLV inside the cells through in situ PCR (tax region). Smear of infected cell lines. FLK—positive control cell line. iSLK-BLV positive (kidney). MCF-7 BLV positive (breast). Antibody control—in situ PCR without primers and TaqPolymerase control, verification of no cross-reaction of anti-dig antibody. In situ PCR with complete reaction. Stain is visualized by DAB reaction against anti-dig system. Images visualized at 40 × and 100 × on a Nikon Eclipse E200 optical microscope. All images were treated with the same conditions of color and contrast.